BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Piñero F, da Fonseca LG. Trial eligibility in advanced hepatocellular carcinoma: Does it support clinical practice in underrepresented subgroups? World J Gastroenterol 2021; 27(24): 3429-3439 [PMID: 34239261 DOI: 10.3748/wjg.v27.i24.3429]
URL: https://www.wjgnet.com/1948-5182/full/v27/i24/3429.htm
Number Citing Articles
1
Leonardo Gomes da Fonseca, Raphael L C Araujo. Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalitiesWorld Journal of Gastroenterology 2022; 28(28): 3573-3585 doi: 10.3748/wjg.v28.i28.3573
2
Ignacio Ventura, Lorena Sanchiz, María Ester Legidos-García, María Teresa Murillo-Llorente, Marcelino Pérez-Bermejo. Atezolizumab and Bevacizumab Combination Therapy in the Treatment of Advanced Hepatocellular CancerCancers 2023; 16(1): 197 doi: 10.3390/cancers16010197
3
Francesco Tovoli, Dante Pio Pallotta, Vito Sansone, Massimo Iavarone, Massimo De Giorgio, Luca Ielasi, Giovan Giuseppe Di Costanzo, Paolo Giuffrida, Rodolfo Sacco, Tiziana Pressiani, Maria Francesca Di Donato, Franco Trevisani, Stefano Fagiuoli, Fabio Piscaglia, Alessandro Granito. Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential TreatmentsTransplantation 2023; 107(1): 156 doi: 10.1097/TP.0000000000004271